Company intelligence / Profile preview

BlueRock Therapeutics

Cambridge, Massachusetts, USAbluerocktx.com ↗

Ownership: Private
Employees: ~200
Development stage: Phase 3

Overview

BlueRock's lead candidate bemdaneprocel for Parkinson's disease has completed Phase 1 trials with positive 18-month data showing no serious adverse events related to cell therapy, sustained neuron cell engraftment, and encouraging trends in motor function. The company is advancing to a Phase 3 registrational trial (exPDite-2) expected to begin in the first half of 2025. Their OpCT-001 therapy for primary photoreceptor diseases has received FDA Fast Track Designation and IND clearance.

Therapeutic areas: OphthalmologyImmunologyCardiovascularNeurology
Modalities: Cell therapyiPSC-derived cell therapyengineered cell therapy
Industry: Biotech

Drug pipeline

5 assets

bemdaneprocel

4 more assets in the full pipeline.

Partnerships

Editas MedicineBayer AG

Beyond the preview

Go deeper on BlueRock Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BlueRock Therapeutics.